The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment
Open accessAbstract
BACKGROUND: Chronic hepatitis C virus (HCV) infection is more prevalent among patients who have chronic kidney disease than among those who do not have the disease. Patients with chronic kidney disease who also have HCV infection are at higher risk for progression to end-stage renal disease than those who have chronic kidney disease without HCV infection. Patients with both HCV infection and advanced chronic kidney disease have limited treatment options. METHODS: We conducted a multicenter, open-label, phase 3 trial to evaluate the efficacy and safety of treatment with the combination of the NS3/4A protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir for 12 weeks in adults who had HCV genotype 1, 2, 3, 4, 5, or 6 infection and also had compensated liver disease (with or without cirrhosis) with severe renal impairment, dependence on dialysis, or both. Patients had stage 4 or 5 chronic kidney disease and either had received no previous treatment for HCV infection or had received previous treatment with interferon or pegylated interferon, ribavirin, sofosbuvir, or a combination of these medications. The primary end point was a sustained virologic response 12 weeks after the end of treatment. RESULTS: Among the 104 patients enrolled in the trial, 52% had genotype 1 infection, 16% had genotype 2 infection, 11% had genotype 3 infection, 19% had genotype 4 infection, and 2% had genotype 5 or 6 infection. The sustained virologic response rate was 98% (102 of 104 patients; 95% confidence interval, 95 to 100). No patients had virologic failure during treatment, and no patients had a virologic relapse after the end of treatment. Adverse events that were reported in at least 10% of the patients were pruritus, fatigue, and nausea. Serious adverse events were reported in 24% of the patients. Four patients discontinued the trial treatment prematurely because of adverse events; three of these patients had a sustained virologic response. CONCLUSIONS: Treatment with glecaprevir and pibrentasvir for 12 weeks resulted in a high rate of sustained virologic response in patients with stage 4 or 5 chronic kidney disease and HCV infection. (Funded by AbbVie; ClinicalTrials.gov number, NCT02651194 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lauer, G. M., & Walker, B. D. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107053450107 · Cited by 2,973
Perz, J. F., Armstrong, G. L., Farrington, L. A., Hutin, Y. J. F., & Bell, B. P. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.05.013 · Cited by 2,572
Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction
Anavekar, N. S., McMurray, J. J. V., Velazquez, E. J., Solomon, S. D., Kober, L., Rouleau, J.-L., White, H. D., Nordlander, R., Maggioni, A., Dickstein, K., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041365 · Cited by 1,917
Panel, A. H. G. (2015) · Hepatology · doi:10.1002/hep.27950 · Cited by 1,382
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Jacobson, I. M., Gordon, S. C., Kowdley, K. V., Yoshida, E. M., Rodriguez-Torres, M., Sulkowski, M. S., Shiffman, M. L., Lawitz, E., Everson, G., Bennett, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214854 · Cited by 1,090
Self-citationEASL Recommendations on Treatment of Hepatitis C 2016
(2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.09.001 · Cited by 985
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
Zeuzem, S., Dusheiko, G. M., Salupere, R., Mangia, A., Flisiak, R., Hyland, R. H., Illeperuma, A., Svarovskaia, E., Brainard, D. M., Symonds, W. T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316145 · Cited by 795
Roth, D., Nelson, D. R., Bruchfeld, A., Liapakis, A., Silva, M., Monsour, H., Martin, P., Pol, S., Londoño, M.-C., Hassanein, T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00349-9 · Cited by 671
Self-citationLeandro, G., Mangia, A., Hui, J., Fabris, P., Rubbia–Brandt, L., Colloredo, G., Adinolfi, L. E., Asselah, T., Jonsson, J. R., Smedile, A., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.03.014 · Cited by 565
Webster, D. P., Klenerman, P., & Dusheiko, G. M. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62401-6 · Cited by 439
Saxena, V., Koraishy, F. M., Sise, M. E., Lim, J. K., Schmidt, M., Chung, R. T., Liapakis, A., Nelson, D. R., Fried, M. W., Terrault, N. A., et al. (2016) · Liver International · doi:10.1111/liv.13102 · Cited by 300
Self-citationExtrahepatic manifestations of chronic hepatitis C virus infection
Cacoub, P., Comarmond, C., Domont, F., Savey, L., Desbois, A. C., & Saadoun, D. (2016) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936115585942 · Cited by 291
Pockros, P. J., Reddy, K. R., Mantry, P. S., Cohen, E., Bennett, M., Sulkowski, M. S., Bernstein, D. E., Cohen, D. E., Shulman, N. S., Wang, D., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.078 · Cited by 278
Self-citationThe Prevalence of Hepatitis C Virus Antibodies among Hemodialysis Patients
Zeldis, J. B., Depner, T. A., Kuramoto, I. K., Gish, R. G., & Holland, P. V. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-12-958 · Cited by 161
Lee, J., Lin, M., Chang, J., Hung, C., Chang, J., Chen, H., Yu, M., & Hwang, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100790 · Cited by 116
Hepatitis C and its impact on renal transplantation
Morales, J., & Fabrizi, F. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.5 · Cited by 88
HCV in Patients With End-Stage Renal Disease
Okoh, E., Bucci, J. R., Simon, J. F., & Harrison, S. A. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01981.x · Cited by 44
Cited by
EASL Recommendations on Treatment of Hepatitis C 2018
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.026 · Cited by 2,827
EASL recommendations on treatment of hepatitis C: Final update of the series☆
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.018 · Cited by 1,252
Panel, A.-I. H. G., Chung, R. T., Ghany, M. G., Kim, A. Y., Marks, K. M., Naggie, S., Vargas, H. E., Aronsohn, A. I., Bhattacharya, D., Broder, T., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy585 · Cited by 717
Spearman, C. W., Dusheiko, G. M., Hellard, M., & Sonderup, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32320-7 · Cited by 404
The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations
Safreed-Harmon, K., Thursz, M., Dillon, J., El-Sayed, M., Elsharkawy, A., Hatzakis, A., Jadoul, M., Prestileo, T., Razavi, H., Rockstroh, J., et al. (2018) · Seminars in Liver Disease · doi:10.1055/s-0038-1666841 · Cited by 257
Self-citation
Metadata
- Authors
- Gane, E., Lawitz, E., Pugatch, D., Papatheodoridis, G., Bräu, N., Brown, A., Pol, S., Leroy, V., Persico, M., Moreno, C., Colombo, M., Yoshida, E. M., Nelson, D. R., Collins, C., Lei, Y., Kosloski, M., & Mensa, F. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-10-12
- Volume
- 377
- Issue
- 15
- Pages
- 1448-1455
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2761085897
- Cited by
- 400
- References
- 17
- FWCI
- 39.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.